12/18
04:39 pm
acad
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [Yahoo! Finance]
12/18
04:05 pm
acad
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Low
Report
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
12/18
01:17 pm
acad
From biotech to defense, here are 10 top stock picks for 2026 from UBS [Yahoo! Finance]
Low
Report
From biotech to defense, here are 10 top stock picks for 2026 from UBS [Yahoo! Finance]
12/18
05:38 am
acad
From biotech to defense, here are 10 top stock picks for 2026 from UBS [Business Insider]
Low
Report
From biotech to defense, here are 10 top stock picks for 2026 from UBS [Business Insider]
12/16
09:11 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $37.00 price target on by analysts at Piper Sandler.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $37.00 price target on by analysts at Piper Sandler.
12/16
09:11 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
12/15
10:05 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/12
08:36 am
acad
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]
12/12
08:00 am
acad
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Neutral
Report
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
12/11
08:44 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.
12/6
12:31 pm
acad
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]
Medium
Report
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]
12/6
10:24 am
acad
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection [Yahoo! Finance]
Medium
Report
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection [Yahoo! Finance]
12/4
06:33 pm
acad
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
Low
Report
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
12/4
01:01 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/3
09:42 am
acad
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
Low
Report
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
12/2
09:03 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.
11/20
04:30 pm
acad
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]
11/20
04:05 pm
acad
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
Low
Report
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
11/17
12:37 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
11/10
04:33 pm
acad
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/9
07:03 pm
acad
Is ACADIA's Raised Guidance and Acquisition Plans Reshaping the Investment Narrative for ACAD? [Yahoo! Finance]
Low
Report
Is ACADIA's Raised Guidance and Acquisition Plans Reshaping the Investment Narrative for ACAD? [Yahoo! Finance]
11/6
10:50 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
11/6
08:10 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a "buy" rating on the stock.
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a "buy" rating on the stock.
11/6
04:37 am
acad
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
12:10 am
acad
ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]